Marcos Milla
Venture Partner @ Samsara BioCapital
San Diego, United States
Marcos Milla is a Series A investor at Samsara BioCapital in San Diego focused on Biotechnology and Health Care. Marcos Milla is the Venture Partner at Samsara BioCapital
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Marcos Milla invests in
Stages Marcos Milla invests in
Countries Marcos Milla invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (60%)
- Health Care 2 (40%)
- Biopharma 1 (20%)
- Therapeutics 1 (20%)
- Pharmaceutical 1 (20%)
Stage
- Series A 2 (40%)
- Series B 2 (40%)
- Seed 1 (20%)
Country
- United States 2 (40%)
- Switzerland 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Enlaza Therapeutics
|
Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $100M / Series A / Apr 30, 2024 | |
Tentarix Biotherapeutics
|
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies. | $35M / Series B / Sep 06, 2023 | |
|
Enlaza Therapeutics
|
Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $61M / Seed / Oct 12, 2022 | |
ImmunOs Therapeutics
|
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $72.9M / Series B / Jun 07, 2022 | |
|
Tentarix Biotherapeutics
|
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies. | $50M / Series A / Oct 14, 2021 |
Co-Investors
About Samsara BioCapital
Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.
Samsara BioCapital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Abraham Bassan
Partner
|
|||
Michael Dybbs
Partner
|
|||
|
Christian Richard
Head of Public Research
|
|||
|
Marcos Milla
Venture Partner
|
|||
Srini Akkaraju
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Marcos Milla invest in?
Marcos Milla invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Marcos Milla?
Public channels for Marcos Milla include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Marcos Milla last invest?
The most recent investment recorded for Marcos Milla closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
